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POLIMORFISME NUKLEOTIDA TUNGGAL PADA GEN ADIPONEKTIN 
DAN PERKAITANNYA DENGAN KEPEKATAN SERUM ADIPONEKTIN 
DAN FAKTOR-FAKTOR RISIKO SINDROM METABOLIK DALAM 
KALANGAN ORANG MELAYU DEWASA 
 
ABSTRAK 
 
Sindrom metabolik ialah kelompok faktor risiko yang termasuk keobesan di 
bahagian pinggang dan perut, hipertrigliseridemia, kolestrol HDL rendah, hipertensi, 
and hiperglisemia. Bukti-bukti terkumpul menyokong hipotesis bahawa 
hipoadiponektinemia meningkatkan lagi risiko terhadap penyakit metabolik. Antara 
yang menarik, sesetengah daripada polimorfisme biasa dalam bahagian promoter, 
exon dan intron 2 pada gen adiponektin manusia mempunyai kaitan dengan faktor-
faktor risiko sindrom metabolik. Kajian ini bertujuan untuk menyiasat perkaitan 
antara beberapa polimorfisme nukleotida tunggal (SNPs) pada gen adiponektin 
dengan kepekatan adiponektin dan faktor-faktor risiko sindrom metabolik dalam 
kalangan orang Melayu dewasa. Seramai 298 orang Melayu dewasa yang terlibat di 
dalam kajian ini. Lilitan pinggang dan tekanan darah telah diukur sebelum darah 
diambil daripada subjek yang telah berpuasa semalaman. Ujian-ujian biokimia untuk 
paras trigliserida, kolestrol HDL dan glukosa dalam darah dijalankan dengan 
menggunakan alatan-alatan komersil. Kepekatan adiponektin plasma diukur 
menggunakan alatan Human Adiponectin ELISA. Sebanyak lima lokasi 
polimorfisme nukleotida tunggal pada gen adiponektin (SNPs -11426, -11391 dan 
-11377 pada bahagian proximal promoter dan SNPs +276 dan +45 pada bahagian 
 xviii 
 
exon 2) telah disaring menggunakan kaedah minipenjujukan. Dapatan kajian ini 
menunjukkan bahawa kepekatan adiponektin pada subjek yang mempunyai sindrom 
metabolik lebih rendah berbanding dengan subjek yang tidak mempunyai sindrom 
metabolik (p < 0.05). Kepekatan adiponektin juga berkait rapat dengan 
hipertrigliseridemia (p < 0.001) dan paras rendah kolestrol HDL (p < 0.001). Tidak 
ada polimorfisme nukleotida tunggal atau haplotip yang menunjukkan perkaitan 
dengan kepekatan adiponektin. Hanya SNP-11426 yang mempunyai kaitan yang 
signifikan dengan sindrom metabolik (p < 0.05), manakala  SNP+276  berkait rapat 
dengan hipertrigliseridemia (p < 0.05) dan haplotip -11426/-11377  mempunyai 
perkaitan dengan hiperglisemia (p < 0.05). Secara keseluruhannya, tidak ada 
interaksi yang signifikan dari segi statistic di antara status sindrom metabolik dan 
polimorfisme nukleotida tunggal atau haplotip dengan kepekatan adiponektin. Walau 
bagaimanapun, terdapat perkaitan yang signifikan antara kepekatan adiponektin dan 
status paras rendah kolestrol HDL dengan SNP-11426 (p < 0.05). Di samping itu, 
terdapat juga perkaitan yang signifikan antara kepekatan adiponektin dan haplotip 
-11426/+45 dengan hipertrigliseridemia (p < 0.05). Kesimpulannya, hipoadiponektin 
dan polimorfisme nukleotida tunggal dan haplotip pada gen adiponektin boleh 
menyumbang kepada perkembangan sindrom metabolik dan faktor-faktor risiko 
melalui mekanisma yang masih lagi tidak diketahui di dalam populasi Melayu.  
 xix 
 
SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) OF ADIPONECTIN 
GENE AND ITS ASSOCIATION WITH SERUM ADIPONECTIN 
CONCENTRATION AND METABOLIC SYNDROME RISK FACTORS 
AMONG MALAY ADULTS 
 
ABSTRACT 
 
Metabolic syndrome is a cluster of risk factors that include central obesity, 
hypertriglyceridaemia, reduced HDL cholesterol, hypertension, and hyperglycemia. 
Accumulating evidences support the hypothesis that hypoadiponectinemia, a type of 
adipokine, confer increased risk for metabolic diseases. Of interest, some of the 
common polymorphisms in the promoter region, exon and intron 2 of the human 
adiponectin gene are associated with risk factors of metabolic syndrome. The present 
study aims to investigate the association of several single nucleotide polymorphisms 
in the adiponectin gene with serum adiponectin concentration and metabolic 
syndrome risk factors among Malay adults. A total of 298 Malay adults were 
recruited in this study. Measurements for waist circumference and blood pressure 
were taken before drawing an overnight fasting blood. Biochemical tests for 
triglycerides, HDL cholesterol and glucose were carried out by using commercially 
available kits. Plasma adiponectin concentration was measured using Human 
Adiponectin ELISA kit. A total of five sites of single nucleotide polymorphisms in 
adiponectin gene (SNPs -11426, -11391 and -11377 at proximal promoter and SNPs 
+276 and +45 at exon 2 regions) were screened using minisequencing method. 
Findings from this study showed that the adiponectin concentration in the subjects 
 xx 
 
with MS was significantly lower than those without MS (p < 0.05). The adiponectin 
concentration was also significantly associated with only hypertriglyceridemia (p < 
0.001) and reduced HDL cholesterol (p < 0.001). None of the studied SNPs or 
haplotypes showed any significant association with the adiponectin concentration. 
Moreover, only SNP-11426 was significantly associated with MS (p < 0.05), while 
SNP+276 was associated with hypertriglyceridemia (p < 0.05), and haplotype 
-11426/-11377 was associated with hyperglycemia (p < 0.05). Overall, there was no 
statistically significant interaction between the status of MS and SNPs or haplotypes 
with respect to the adiponectin concentration. However, there was a significant 
association between the adiponectin concentration and status of reduced HDL 
cholesterol with SNP-11426 (p < 0.05). Besides, a significant association was also 
observed in the adiponectin concentration and hypertriglyceridemia with haplotype 
-11426/+45 (p < 0.05). In conclusion, hypoadiponectinemia and SNPs and 
haplotypes of adiponectin gene may contribute to the development of metabolic 
syndrome and its risk factors, via unknown mechanisms in Malay population. 
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CHAPTER ONE: INTRODUCTION 
1.1 General Introduction 
Metabolic syndrome (MS) is an emerging public health problem throughout the 
world due to increase in the prevalence of the individual metabolic abnormalities i.e 
central obesity, hypertriglyceridaemia (the elevated serum triglyceride), reduced 
high-density lipoprotein cholesterol (HDL cholesterol), hypertension, and 
hyperglycemia (the elevated blood glucose levels) (Alberti et al., 2005). The rise of 
MS cases was shown to be in parallel with the prevalence of obesity (Grundy, 2008). 
A comprehensive overview on MS pandemic in the America, Europe and India 
indicates more than 20 % of the adult populations as having MS (Grundy, 2008). The 
prevalence of MS recorded was 22.2 % in Italy, 23.9 % in Portugal, 46 % in the 
Netherlands, 41.8 % in Greece, 37 % in Finland and Asians especially India was 41.1 
%, Thailand was 12.8 %, China was 13.2 % and Japan was 14.9 % (Grundy, 2008). 
Across the Southeast Asia, there are several countries such as Singapore and 
Thailand that are actively involved in evaluating the MS. Tan et al. (2004) reported 
that in Singapore, the Asian Indian had the highest prevalence of MS followed by the 
Malays and Chinese (Tan et al., 2004). In contrast, a different study in Singapore 
suggested that Malay women were more likely to develop hypertension in 
association with insulin resistance, as compared to Chinese and Asian Indian (Ang et 
al., 2005). Moreover, hyperuricemia and elevated levels of liver enzymes, which 
were claimed to have association with MS, have been reported among Thai adults 
(Lohsoonthorn et al., 2006; Perera et al., 2008). Although Malaysia is still lacking of 
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the representative data on MS, but the neighboring countries somehow reflect the 
condition of the syndrome herein as we govern the same major ethnics groups i.e 
Malays, Asian Indians and Chinese.  
The mechanisms underlying MS are still not fully understood; however, 
accumulating studies have proposed an association between adiponectin; a type of 
adipokines with MS risk factors. Several studies have demonstrated low adiponectin 
concentration (hypoadiponectinemia) as a common denominator for the MS risk 
factors. The negative correlation between visceral adiposity and adiponectin 
concentration suggests that hypoadiponectinemia is related to central obesity 
(Matsuzawa, 2010; Ryo et al., 2004). Clinical reports have pointed out earlier that 
there are positive associations between the circulating adiponectin concentration with 
the HDL cholesterol and inverse association with triglycerides (Kazumi et al., 2004; 
Matsubara et al., 2002). In addition, lower concentrations of adiponectin were 
observed in individuals with hypertension (Adamczak et al., 2003; Iwashima et al., 
2004) and type 2 diabetes (T2D) (Hotta et al., 2000; Lindsay et al., 2002). From 
these evidences, it can be seen that adiponectin is a potential biomarker for the MS 
and its risk factors. Moreover, researchers have suggested that adiponectin can be a 
promising therapeutic agent for MS and its risk factors. It was proposed that by 
increasing circulating adiponectin concentration or enhancing adiponectin signaling 
through its receptors could promisingly tackle the root that cause the MS (Zhu et al., 
2008). Although the claims excited many researchers, a lot of future investigations 
are required to support the matter.  
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Despite the regulation of adiponectin expression in targeting MS which 
remains ambiguous, there has been growing interest in adiponectin gene that is 
deemed as potential genetic contributor to MS. Several studies have recently reported 
the genetic polymorphisms and linkages between adiponectin gene and MS. For 
instance, a genotype screening that was performed on 811 Hispanic individuals has 
demonstrated an association between genetic variations or single nucleotide 
polymorphisms (SNPs) in the adiponectin gene particularly in the promoter region 
with obesity, especially the visceral obesity (Sutton et al., 2005). However, the 
genetic variants of adiponectin and hypertriglyceridaemia and reduced HDL 
cholesterol were less explored and scantly reported (Yang & Chuang, 2006). A study 
to determine the possible effects of variation in adiponectin gene has shown that the 
mutant allele T of SNP+276 was associated with the elevated diastolic blood 
pressure whereas the wild-type allele T of SNP+45 demonstrated its protective role 
as it was associated with high HDL cholesterol levels (Mousavinasab et al., 2006). 
On the other hand, Zacharova et al. (2005) which aimed to investigate the selected 
SNPs of the adiponectin gene and T2D reported that mutant allele G of SNP+45 was 
a predictor for T2D (Zacharova et al., 2005). 
Taking together, hypoadiponectinemia and genetic variants of adiponectin 
gene play an important role in the pathogenesis of MS. Studies on the influence of 
the different ethnic groups is crucial to promote in-depth understanding on the 
regulation of MS, adiponectin and adiponectin gene. In this context, this present 
study was designed to investigate the association of several SNPs in adiponectin 
gene with serum adiponectin concentration and MS risk factors among Malay adults.
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1.2 Literature Reviews 
1.2.1 Metabolic Syndrome 
The MS has become one of the major public-health challenges worldwide. Grundy 
(2008) mentioned in his review that MS has a long history as early as 1923 when 
scientists began to notice the cluster of insulin resistance, hyperglycaemia, 
hypertension, low HDL cholesterol, and raised triglycerides as common risk factors 
for cardiovascular disease (Grundy, 2008). Since then, several names appeared to 
describe the cluster. Waine (2005) has reviewed previous studies on MS and 
summarized the names that have been used over the decades, such as the insulin 
resistance syndrome, plurimetabolic syndrome, dysmetabolic syndrome, and the 
deadly quartet (Waine, 2005). The term MS was first used by the World Health 
Organization (WHO) in 1998 which proposed a unifying definition for the syndrome 
by taking abnormal glucose tolerance as a core factor. A year later, European Group 
for the Study of Insulin Resistance (EGIR) came out with a modified version of the 
WHO recommendation (Zimmet et al., 2005). The National Cholesterol Education 
Program’s Adult Treatment Program III (ATP III) in 2001 then clinically defined MS 
by proposing abdominal obesity, dyslipidemia, hypertension, insulin resistance and 
prothrombotic and inflammatory states as the key components (Gable et al., 2007). 
This was followed by the International Diabetes Federation (IDF) recommendations 
on 2005 (Zimmet et al., 2005) which prioritized ethnicity-specific waist 
circumference cut-off points as a measure for central obesity apart from other known 
risk factors. The IDF definition was constructed in such a way that it would rapidly 
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identify individuals at risk without eliminating the ethnic factor. Due to its simplicity 
and appropriateness to our population, the IDF definition was used throughout the 
present study. Table 1 listed the criteria used for diagnosing MS by IDF definition. 
Note that throughout the thesis, hyperglycemia (excessive amount of glucose 
circulates in the blood plasma) and T2D (characterized by hyperglycemia and caused 
by insufficient insulin production to regulate the circulating glucose) (Sheng & 
Yang, 2008) were used interchangeably. 
Moreover, Lahiry et al, (2008) has described that the concept of MS helped to 
emphasize on the risk of vascular disease related to central obesity and previously 
overlooked biomarkers such as serum triglycerides (Lahiry et al., 2008). Intense 
studies devoted to understand the MS risk factors especially the central obesity, 
adipose tissue and adipokines have eventually lead the scientists to the discovery of 
the adiponectin; a type of adipose-specific serum protein.  
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Table 1 International Diabetes Federation definition of the metabolic 
syndrome (Zimmet et al., 2005) 
1
Following the ethnic-specific measurement of South Asian; 
2
HDL cholesterol: high-
density lipoprotein cholesterol.  
No Risk Factors Measurement Sex Readings 
1. Central obesity Waist  circumference
1
 
Men ≥ 90 cm 
Women ≥ 80 cm 
 
Plus any 2 of the following 
2. Hypertension 
Systolic blood pressure / 
Diastolic blood pressure  
(or  received treatment of 
previously diagnosed 
hypertension) 
Both 
≥ 130/85 
mmHg 
3. Hyperglycemia 
Fasting plasma glucose  
(or  previously diagnosed 
type 2 diabetes) 
Both 
≥ 5.6 mmol/L 
(100 mg/dL) 
4. 
 
Reduced HDL 
cholesterol
2
 
HDL cholesterol  
(or specific treatment for 
this lipid abnormality) 
Men 
<1.0 mmol/L 
(40 mg/dL) 
Women 
<1.3 mmol/L 
(50 mg/dL) 
5. Hypertriglyceridemia 
Triglycerides  
(or specific treatment for 
this lipid abnormality) 
Both 
≥ 1.7 mmol/L 
(150 mg/dL) 
 7 
 
1.2.2 Adipocytokines 
Adipose tissue has been considered as an active endocrine due to the production of 
vital hormones called adipocytokines (also known as adipokines) which significantly 
involved in the regulation of body’s homeostasis (Koerner et al., 2005). There are 
two types of adipose tissue i.e the brown adipose tissue (BAT) and white adipose 
tissue (WAT) (Gu, 2009). BAT mainly involves in generating the heat by triggering 
the combustion of lipids and glucose in the tissue (Cannon & Nedergaard, 2004). On 
the other hand, WAT is of interest due to its role as the primary site in producing the 
most important adipocytokines such as adiponectin, leptin, zinc-α2-glycoprotein 
(ZAG), various interleukins, transforming growth factor-β (TGF-β), monocyte 
chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF), 
nerve growth factor (NGF), tumor necrosis factor-α (TNF-α), and plasminogen 
activator inhibitor-1 (PAI-1) (Figure 1) (Trayhurn et al., 2006). Leptin, for instance, 
has been investigated for its role in energy homeostasis, glucose and lipid 
metabolism, and immune and neuroendocrine function (Ahima, 2006), while the 
interleukins have been emphasized as markers for inflammation (Trayhurn et al., 
2006).  
The WAT is mainly located in the subcutaneous region and viscera, hence 
closely associated with the pathogenesis of obesity-related disorders (Ahima, 2006). 
The adiponectin that is abundantly secreted by WAT has received much attention 
due to its protective role against the obesity-related diseases (Gu, 2009; Koerner et 
al., 2005).   
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Figure 1  Major adipokines secreted from white adipose tissue (Trayhurn et al., 
2006) 
 
Note:  
IL-1β  Interleukins 1β  
IL-6  Interleukins 6 
IL-8  Interleukins 8 
IL-10  Interleukins 10 
MCP-1 Monocyte chemoattractant protein-1 
MIF  Macrophage migration inhibitory factor  
NGF  Nerve growth factor  
PAI-1  Plasminogen activator inhibitor-1  
TGF-β  Transforming growth factor-β  
TNF-α  Tumor necrosis factor-α 
VEGF  Vascular endothelial growth factor  
ZAG  Zinc-α2-glycoprotein
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1.2.3 Adiponectin  
Various adipocyte-derived secretory proteins have been increasingly linked to MS. 
Adiponectin, another type of adipokines recently attracts much attention among 
scientists. It is a hormone extensively secreted by adipocytes, expressed inversely to 
total fat (Comuzzie et al., 2001) and acted as anti-diabetic, anti-inflammatory and 
anti-atherogenic agents (Broedl et al., 2006). Adiponectin belongs to the complement 
1q family and comprises four domains; an amino-terminal collagen-like sequence, a 
variable region, a collagenous domain and a carboxy-terminal globular domain 
(Garaulet et al., 2007; Kadowaki & Yamauchi, 2005). This protein is constructed by 
244 amino acids with a molecular weight of 26,414 Da and typically exists in three 
forms; low molecular weight (LMW) hexamers, medium molecular weight (MMW) 
and high molecular weight (HMW) multimeric structures (Gu, 2009; Kadowaki & 
Yamauchi, 2005). Adiponectin can be found extensively in serum ranging from 5 to 
30 μgml-1 (Garaulet et al., 2007). Table 2 represents the variety of multimeric forms 
of adiponectin.  
This hormone was reported to function in two ways; 1) anti-atherosclerotic 
actions and 2) insulin-sensitizing actions, through a number of mechanisms. As 
shown in Figure 2, Wiecek et al. (2007) in a review paper on adiponectin has 
summarized the anti-atherogenic actions of adiponectin that suppresses the 
production of tumour necrosis factor-α (TNF- α), modulates biological actions of 
growth factors by binding with platelet-derived growth factor BB (PDGF-BB), basic 
fibroblast growth factor (FGF), and heparin-binding epidermal growth factor-like 
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growth factor (HB EGF), reduces accumulation of lipids in human monocyte-derived 
macrophages, inhibits transformation of macrophages into foam cells by 
down-regulating scavenger receptors, suppresses superoxide generation, decreases 
the expression of adhesion molecules (VCAM-1; ICAM-1, E-selectin), increases 
expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in infiltrating 
macrophages, and last but not least increases activity of endothelial nitric oxide (NO) 
synthase (Wiecek et al., 2007). Figure 2 summarizes the insulin-sensitizing action of 
adiponectin which stimulates glucose utilization and fatty acid oxidation in skeletal 
muscles and in the liver, enhances insulin signalling in skeletal muscle, facilitates 
glucose uptake and suppresses gluconeogenesis in the liver (Wiecek et al., 2007). 
This mechanism of actions of adiponectin ultimately results in increasing insulin 
sensitivity and suppression of atherosclerosis (Kadowaki & Yamauchi, 2005). Since 
this type of protein characterizes a number of metabolic derangements, it is crucial to 
have insights into its molecular level.  
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Table 2 Multimeric forms of adiponectin (Wiecek et al., 2007) 
Structures Multimeric Forms Molecular Weight 
 
Globular C-terminal 
domain fragments 
None 
 
Monomer 
 
Trimer 
Low Molecular Weight 
(LMW) 
 
Hexamer 
Medium Molecular 
Weight (MMW) 
 
12-mers 
High Molecular Weight 
(HMW) 
 
18-mers 
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Figure 2 Anti-atherogenic and of insulin-sensitizing actions of adiponectin 
(Wiecek et al., 2007) 
 
Note: 
FGF  Fibroblast growth factor 
HB EGF Heparin-binding epidermal growth factor 
ICAM-1  Intercellular adhesion molecule-1 
NO  Nitric oxide 
PDGF-BB Platelet-derived growth factor BB 
TIMP-1 Tissue inhibitor of metalloproteinase-1 
TNF- α Tumour necrosis factor-α 
VCAM-1 Vascular cell adhesion molecule-1  
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1.2.4 Adiponectin Gene 
Despite of extensive studies correlating environmental factors such as high fat diet 
and physical inactivity with the pathogenesis of MS, there is also strong evidence 
showing that the syndrome is possibly inheritable (Lyssenko et al., 2008). Groop 
(2000) listed possible genes which are associated with fat and glucose metabolism 
such as genes for leptin/leptin receptor, β2- and β3- adrenergic receptors, lipases, 
TNF-α, PPAR-γ, glycoprotein PC-1, IRS-1 and lycogen synthase (Groop, 2000). 
Apart from these genes, there is an increase of interest among scientists to focus 
more onto adiponectin gene recently. 
The 16-kb structural gene, which has been mapped to chromosome 3 (3q27) 
in the human APM1/ACDC/ADIPOQ gene, encodes the protein product adiponectin 
(Comuzzie et al., 2001). This particular region of chromosome 3 (Accession ID 
D45371) has also been found to contain a quantitative trait locus (QTL) with a strong 
influence on phenotypes of the MS (Kissebah et al., 2000). The adiponectin gene 
contains three exons and two introns (Gable et al., 2006; Gable et al., 2007; 
Kadowaki & Yamauchi, 2005). Exon 1 and 2 are 76 and 222 bp, respectively, with 
10.3 kb of intron 1 lies in between them while exon 3 is approximately 4.28 kb. The 
translation starts at exon 2 and ends at exon 3, leaving exon 1 and part of exon 3 
untranslated (Takahashi et al., 2000).  Figure 3 and 4 show the ideogram and 
genomic organization of the adiponectin gene, respectively.  
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Figure 3 Ideogram of chromosome 3 where adiponectin spanned on 3q27 
(National Center for Biotechnology Information, 2008) 
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Figure 4 Organization of the adiponectin gene on chromosome 3 (Vasseur et al., 2006) 
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1.2.5 Association of Adiponectin, Adiponectin Gene and Metabolic Syndrome 
The discovery of adiponectin back in 1995 (Scherer et al., 1995) did not receive 
major attention in the scientific community for the next few years until its markedly 
protective role in the pathogenesis of obesity-related disorders was acknowledged in 
the new millennium. Yang and Chuang (2006) in their review article on human 
genetics of adiponectin in the MS claimed that this adipose-derived serum protein is 
an important biomarker for MS.  
The human genetic studies not only allow scientists to have an insight into 
various SNPs and genetic make-up of adiponectin, but also provide information and 
strong evidence to support the fact that this gene is one of the contributing factors to 
MS (Yang et al., 2007). Studies demonstrated that serum adiponectin concentration 
is significantly low in subjects with obesity, insulin resistance, MS, T2D, and 
coronary heart disease (Broedl et al., 2006; Yang & Chuang, 2006; Yang et al., 
2007). Scientists also found a number of variants of SNPs and missense mutations in 
European, North American and Japanese populations that are closely linked to the 
MS risk factors (Broedl et al., 2006; Gable et al., 2006). However, the association of 
adiponectin genetic variations with dyslipidemia and blood pressure was poorly 
explored (Yang & Chuang, 2006).  
Three regions that are closely linked to MS have been identified on the highly 
polymorphic adiponectin gene; 1) the 5’ sequences; 2) the intron 2-exon 2 region, 
and 3) exon 3 (Vasseur et al., 2006). This is supported by Gable et al. (2007) which 
claimed that the promoter variants -11391G>A and -11377C>G, +45T>G variant of 
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exon 2 and +276G>T variant of intron 2 are the most widely studied; all mentioned 
variants were selected in this present study. Yang and Chuang (2006) also agreed 
with the fact that promoter region, exon and intron 2, and the rare non-synonymous 
mutations in exon 3 harbor a number of common polymorphisms across different 
ethnic population (Yang & Chuang, 2006). When these polymorphisms were 
translated, all the mentioned SNPs excluding the -11391G>A introduced changes to 
the amino acid (Table 3).  
Various studies demonstrated that SNP+276 is associated with increased risk 
of T2D, higher insulin resistance index, lower adiponectin concentration, 
cardiovascular disease risk, higher BMI, higher glucose level and obesity (Filippi et 
al., 2004; Hara et al., 2002; Jang et al., 2006; Ukkola et al., 2003; Xita et al., 2005; 
Yang et al., 2007). Kadowaki and Yamauchi (2005) addressed that SNP+276 as one 
of the factors in reducing adiponectin concentration and in turn promote the 
development of insulin resistance, MS and atherosclerosis (Kadowaki & Yamauchi, 
2005). 
Haplotype of a variant with other variants perhaps doubled the effect on MS 
susceptibility. The haplotype +276/+45 was the most common haplotype studied that 
linked with higher body weight, waist circumference, blood pressure, HDL 
cholesterol/total cholesterol ratio, lower serum adiponectin and higher risk of T2D 
(Gable et al., 2006). SNP+45, located in exon 2 is a silent mutation which could 
possibly alter a putative enhancer or silencer of splicing (Vasseur et al., 2003). On 
the other hand, SNP+276 is located in intronic region (intron 2) which is well 
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documented as non-coding region.  However, studies have proposed that unknown 
mechanism(s) of these intronic SNPs perhaps involved in the expression level of the 
adiponectin gene that ultimately cause the development of MS (Hara et al., 2002; 
Jang et al., 2006). 
Moreover, a study on French Caucasian population disclosed association 
between SNP-11391 and SNP-11377 with serum adiponectin concentration and 
diabetic status (Vasseur et al., 2003). The SNP-11391 was also associated with 
hypoadiponectinemia in Amish (people devoted to Christian living in Canada or 
United States) and Swedish population while SNP-11377 was associated with T2D in 
Japanese population. SNP-11426 has been shown to be associated with variation in 
insulin sensitivity in French and Swedish population (Gable et al., 2006). Gu (2009) 
has summarized SNPs of adiponectin gene that have been associated with MS risk 
factors in various ethnic populations as shown in Table 4 (Gu, 2009).  
Although the genetic variation in 5’ sequences has not yet been defined to 
cause the development of MS, but these variants were shown to be associated with 
adverse metabolic features. Furthermore, SNPs in adiponectin gene have been 
demonstrated to contribute to hypoadiponectinemia, decreased insulin sensitivity and 
T2D in several populations. Therefore, these SNPs are thought to either modulate the 
expression of the adiponectin gene or in linkage disequilibrium with functional 
variants to modulate the expression of the gene (Vimaleswaran et al., 2008). There 
are several other variants contributing to the MS, with some probably still unknown. 
Thus, in depth investigations are crucial to precisely determine which variant(s) leads 
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a significant role to the risk of MS. Taken all the consideration from previous studies 
as a whole, therefore the presence of SNPs +45, +276, -11426, -11391 and -11377 
were shown to be worthy predictors to indicate the characteristics of MS in Malay 
population. 
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Table 3 Amino acid changes introduced by respective SNPs in adiponectin gene 
SNP Nucleotide Amino Acid Sequence 
+45T>G 
T 
91    TTG CTG GGA GCT GTT CTA CTG CTA TTA GCT CTG CCC GGT CAT GAC   135 
31    Leu Leu Gly Ala Val Leu Leu Leu Leu Ala Leu Pro Gly His Asp   45 
 
136   CAG GAA ACC ACG ACT CAA GGG CCC GGA GTC CTG CTT CCC CTG CCC   180 
46    Gln Glu Thr Thr Thr Gln Gly Pro Gly Val Leu Leu Pro Leu Pro   60 
G 
91    TTG CTG GGA GCT GTT CTA CTG CTA TTA GCT CTG CCC GGG CAT GAC   135 
31    Leu Leu Gly Ala Val Leu Leu Leu Leu Ala Leu Pro Gly His Asp   45 
 
136   CAG GAA ACC ACG ACT CAA GGG CCC GGA GTC CTG CTT CCC CTG CCC   180 
46    Gln Glu Thr Thr Thr Gln Gly Pro Gly Val Leu Leu Pro Leu Pro   60 
Note: The single nucleotide change from T to G at SNP+45 does not alter the amino acid in the protein chain. 
+276G>T 
G 
586   ATG AAG GAT GTG AAG GTC AGC CTC TTC AAG AAG GAC AAG GCT ATG   630 
196   Met Lys Asp Val Lys Val Ser Leu Phe Lys Lys Asp Lys Ala Met   210 
 
631   CTC TTC ACC TAT GAT CAG TAC CAG GAA AAT AAT GTG GAC CAG GCC   675 
211   Leu Phe Thr Tyr Asp Gln Tyr Gln Glu Asn Asn Val Asp Gln Ala   225 
T 
586   ATG AAG GAT GTG AAG TTC AGC CTC TTC AAG AAG GAC AAG GCT ATG   630 
196   Met Lys Asp Val Lys Phe Ser Leu Phe Lys Lys Asp Lys Ala Met   210 
 
631   CTC TTC ACC TAT GAT CAG TAC CAG GAA AAT AAT GTG GAC CAG GCC   675 
211   Leu Phe Thr Tyr Asp Gln Tyr Gln Glu Asn Asn Val Asp Gln Ala   225 
Note: The single nucleotide change from G to T at SNP+276 alters the amino acid from valine to phenylalanine in 
the protein chain.  
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+11426A>G 
A 
2746  TAG TAA AGA CAG GGT TTC ACC ATA TTG GCC AGG CTG GTC TCG AAC   2790 
916   End End Arg Gln Gly Phe Thr Ile Leu Ala Arg Leu Val Ser Asn   930 
 
2791  TCC TGA CCT TGT GAT CTG CCC GCC TCC ATT TTT GTT GTT ATT TTT   2835 
931   Ser End Pro Cys Asp Leu Pro Ala Ser Ile Phe Val Val Ile Phe   945 
G 
2746  TAG TAA AGA CAG GGT TTC ACC ATA TTG GCC AGG CTG GTC TCG AGC   2790 
916   End End Arg Gln Gly Phe Thr Ile Leu Ala Arg Leu Val Ser Ser   930 
 
2791  TCC TGA CCT TGT GAT CTG CCC GCC TCC ATT TTT GTT GTT ATT TTT   2835 
931   Ser End Pro Cys Asp Leu Pro Ala Ser Ile Phe Val Val Ile Phe   945 
Note: The single nucleotide change from A to G at SNP+11426 alters the amino acid from asparagine to serine in 
the protein chain. 
-11391G>A 
G 
3151  GTT TCC CTC CCG ATA TCA AAA AGA CTG TGG CCT GCC CAG CTC TCG   3195 
1051  Val Ser Leu Pro Ile Ser Lys Arg Leu Trp Pro Ala Gln Leu Ser   1065 
 
3196  TAT CCC CAA GCC ACA CCA TCT GGC TAA ATG GAC ATC ATG TTT TCT   3240 
1066  Tyr Pro Gln Ala Thr Pro Ser Gly End Met Asp Ile Met Phe Ser   1080 
A 
3151  GTT TCC CTC CCG ATA TCA AAA AGA CTG TGG CCT GCC CAG CTC TCA   3195 
1051  Val Ser Leu Pro Ile Ser Lys Arg Leu Trp Pro Ala Gln Leu Ser   1065 
 
3196  TAT CCC CAA GCC ACA CCA TCT GGC TAA ATG GAC ATC ATG TTT TCT   3240 
1066  Tyr Pro Gln Ala Thr Pro Ser Gly End Met Asp Ile Met Phe Ser   1080 
Note: The single nucleotide change from G to A at SNP-11391 does not alter the amino acid in the protein chain. 
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-11377C>G 
C 
1396  ACG TCC TGT CTT GGA AGG ACT ACT ACT CAA TGG CCC CTG CAC TAC   1440 
466   Thr Ser Cys Leu Gly Arg Thr Thr Thr Gln Trp Pro Leu His Tyr   480 
 
1441  TCT ACT TCC TCT TAC CTA TGT CCC TTC TCA TGC CTT TCC CTC CAA   1485 
481   Ser Thr Ser Ser Tyr Leu Cys Pro Phe Ser Cys Leu Ser Leu Gln   495 
G 
1396  ACG TCC TGT CTT GGA AGG ACT ACT ACT CAA TGG CCC CTG GAC TAC   1440 
466   Thr Ser Cys Leu Gly Arg Thr Thr Thr Gln Trp Pro Leu Asp Tyr   480 
 
1441  TCT ACT TCC TCT TAC CTA TGT CCC TTC TCA TGC CTT TCC CTC CAA   1485 
481   Ser Thr Ser Ser Tyr Leu Cys Pro Phe Ser Cys Leu Ser Leu Gln   495 
Note: The single nucleotide change from C to G at SNP-11377 alters the amino acid from histidine to aspartic acid 
in the protein chain.  
\ 
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Table 4 The genetic variants and adiponectin or MS risk factors with the 
respective ethnic group that has been studied (Gu, 2009) 
SNP Adiponectin or MS Risk Factors Ethnic Group 
+45 
Adiponectin concentration Japanese, Chinese 
Type 2 diabetes Korean, Italian, Quebec family study 
Obesity Swedish, Finnish 
+276 
Adiponectin concentration European Caucasians 
Type 2 diabetes Japanese, Italian, German 
Obesity Chinese, Korean 
-11377 
Adiponectin concentration French Caucasians 
Type 2 diabetes Swedish, Danish 
Obesity German, Italian 
-11391 
Adiponectin concentration French Caucasians 
Type 2 diabetes UK Caucasian women 
Obesity German, Italian 
-11426 
Adiponectin concentration French Caucasians, Swedish, 
Type 2 diabetes European Caucasians 
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1.3 Rationale of the Study 
In regards to the gradual increase in prevalence of MS risk factors, Song et al. (2006) 
have pointed out the needs to identify susceptibility genes of MS and its mechanism 
of actions, which may enable the investigators to design preventive strategies and 
targeted treatments (Song et al., 2006). To date, there is still lack of nationally 
representative figures on occurrence and association of adiponectin and MS among 
Malay adults in Malaysia, let alone their association with the polymorphisms.  
Human genetic epidemiological studies on adiponectin and parameters of MS 
would be helpful to understand the molecular mechanisms involved in regulating 
metabolism susceptibility hence protect against the development of metabolic 
diseases. Moreover, metabolic diseases appear to be varied across different 
population and ethnicity. As the ethnic differences strongly suggest a genetic 
component in the pathogenesis of metabolic syndrome (Song et al., 2006), therefore, 
this study perhaps will provide an insight on the underlying causes to prevent or 
reduce the long-term risks for MS among Malay population.  
 
1.4 Objectives 
1.4.1 General Objectives 
To investigate the association of the selected SNPs in adiponectin gene with serum 
adiponectin concentration and MS risk factors among Malay adults.  
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1.4.2 Specific Objectives 
1. To determine the prevalence of SNPs +45, +276, -11426, -11391 and -11377 of 
the adiponectin gene among Malay adults.  
2. To investigate the association between serum adiponectin concentration with the 
MS and MS risk factors.  
3. To investigate the association between the selected SNPs and haplotypes with 
serum adiponectin concentration.  
4. To investigate the association between the selected SNPs and haplotypes with the 
MS and MS risk factors. 
  
